Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 66

1.

Transcription Factor PU.1 Promotes Conventional Dendritic Cell Identity and Function via Induction of Transcriptional Regulator DC-SCRIPT.

Chopin M, Lun AT, Zhan Y, Schreuder J, Coughlan H, D'Amico A, Mielke LA, Almeida FF, Kueh AJ, Dickins RA, Belz GT, Naik SH, Lew AM, Bouillet P, Herold MJ, Smyth GK, Corcoran LM, Nutt SL.

Immunity. 2019 Jan 15;50(1):77-90.e5. doi: 10.1016/j.immuni.2018.11.010. Epub 2019 Jan 2.

PMID:
30611612
2.

Foxp1 Is Indispensable for Ductal Morphogenesis and Controls the Exit of Mammary Stem Cells from Quiescence.

Fu NY, Pal B, Chen Y, Jackling FC, Milevskiy M, Vaillant F, Capaldo BD, Guo F, Liu KH, Rios AC, Lim N, Kueh AJ, Virshup DM, Herold MJ, Tucker HO, Smyth GK, Lindeman GJ, Visvader JE.

Dev Cell. 2018 Dec 3;47(5):629-644.e8. doi: 10.1016/j.devcel.2018.10.001. Epub 2018 Oct 25.

PMID:
30523786
3.

VDAC2 enables BAX to mediate apoptosis and limit tumor development.

Chin HS, Li MX, Tan IKL, Ninnis RL, Reljic B, Scicluna K, Dagley LF, Sandow JJ, Kelly GL, Samson AL, Chappaz S, Khaw SL, Chang C, Morokoff A, Brinkmann K, Webb A, Hockings C, Hall CM, Kueh AJ, Ryan MT, Kluck RM, Bouillet P, Herold MJ, Gray DHD, Huang DCS, van Delft MF, Dewson G.

Nat Commun. 2018 Nov 26;9(1):4976. doi: 10.1038/s41467-018-07309-4.

4.

A point mutation in the Ncr1 signal peptide impairs the development of innate lymphoid cell subsets.

Almeida FF, Tognarelli S, Marçais A, Kueh AJ, Friede ME, Liao Y, Willis SN, Luong K, Faure F, Mercier FE, Galluso J, Firth M, Narni-Mancinelli E, Rais B, Scadden DT, Spallotta F, Weil S, Giannattasio A, Kalensee F, Zöller T, Huntington ND, Schleicher U, Chiocchetti AG, Ugolini S, Herold MJ, Shi W, Koch J, Steinle A, Vivier E, Walzer T, Belz GT, Ullrich E.

Oncoimmunology. 2018 Aug 15;7(10):e1475875. doi: 10.1080/2162402X.2018.1475875. eCollection 2018.

5.

GM-CSF Quantity Has a Selective Effect on Granulocytic vs. Monocytic Myeloid Development and Function.

Sun L, Rautela J, Delconte RB, Souza-Fonseca-Guimaraes F, Carrington EM, Schenk RL, Herold MJ, Huntington ND, Lew AM, Xu Y, Zhan Y.

Front Immunol. 2018 Aug 28;9:1922. doi: 10.3389/fimmu.2018.01922. eCollection 2018.

6.

Characterisation of mice lacking the inflammatory caspases-1/11/12 reveals no contribution of caspase-12 to cell death and sepsis.

Salvamoser R, Brinkmann K, O'Reilly LA, Whitehead L, Strasser A, Herold MJ.

Cell Death Differ. 2018 Aug 28. doi: 10.1038/s41418-018-0188-2. [Epub ahead of print]

PMID:
30154447
7.

Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use.

Brennan MS, Chang C, Tai L, Lessene G, Strasser A, Dewson G, Kelly GL, Herold MJ.

Blood. 2018 Oct 11;132(15):1573-1583. doi: 10.1182/blood-2018-06-859405. Epub 2018 Aug 23.

PMID:
30139826
8.

TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1.

Lionnard L, Duc P, Brennan MS, Kueh AJ, Pal M, Guardia F, Mojsa B, Damiano MA, Mora S, Lassot I, Ravichandran R, Cochet C, Aouacheria A, Potts PR, Herold MJ, Desagher S, Kucharczak J.

Cell Death Differ. 2018 Jul 24. doi: 10.1038/s41418-018-0169-5. [Epub ahead of print]

PMID:
30042493
9.

Mining the Plasma Cell Transcriptome for Novel Cell Surface Proteins.

Trezise S, Karnowski A, Fedele PL, Mithraprabhu S, Liao Y, D'Costa K, Kueh AJ, Hardy MP, Owczarek CM, Herold MJ, Spencer A, Shi W, Willis SN, Nutt SL, Corcoran LM.

Int J Mol Sci. 2018 Jul 24;19(8). pii: E2161. doi: 10.3390/ijms19082161.

10.

MARCH1-mediated ubiquitination of MHC II impacts the MHC I antigen presentation pathway.

Wilson KR, Liu H, Healey G, Vuong V, Ishido S, Herold MJ, Villadangos JA, Mintern JD.

PLoS One. 2018 Jul 12;13(7):e0200540. doi: 10.1371/journal.pone.0200540. eCollection 2018.

11.

DNA repair processes are critical mediators of p53-dependent tumor suppression.

Janic A, Valente LJ, Wakefield MJ, Di Stefano L, Milla L, Wilcox S, Yang H, Tai L, Vandenberg CJ, Kueh AJ, Mizutani S, Brennan MS, Schenk RL, Lindqvist LM, Papenfuss AT, O'Connor L, Strasser A, Herold MJ.

Nat Med. 2018 Jul;24(7):947-953. doi: 10.1038/s41591-018-0043-5. Epub 2018 Jun 11.

PMID:
29892060
12.

Loss of NF-κB1 Causes Gastric Cancer with Aberrant Inflammation and Expression of Immune Checkpoint Regulators in a STAT-1-Dependent Manner.

O'Reilly LA, Putoczki TL, Mielke LA, Low JT, Lin A, Preaudet A, Herold MJ, Yaprianto K, Tai L, Kueh A, Pacini G, Ferrero RL, Gugasyan R, Hu Y, Christie M, Wilcox S, Grumont R, Griffin MDW, O'Connor L, Smyth GK, Ernst M, Waring P, Gerondakis S, Strasser A.

Immunity. 2018 Mar 20;48(3):570-583.e8. doi: 10.1016/j.immuni.2018.03.003.

PMID:
29562203
13.

CRISPR/Cas9: A tool for immunological research.

Hochheiser K, Kueh AJ, Gebhardt T, Herold MJ.

Eur J Immunol. 2018 Apr;48(4):576-583. doi: 10.1002/eji.201747131. Epub 2018 Feb 26. Review.

PMID:
29415333
14.

Anti-apoptotic A1 is not essential for lymphoma development in Eµ-Myc mice but helps sustain transplanted Eµ-Myc tumour cells.

Mensink M, Anstee NS, Robati M, Schenk RL, Herold MJ, Cory S, Vandenberg CJ.

Cell Death Differ. 2018 Mar;25(4):795-806. doi: 10.1038/s41418-017-0045-8. Epub 2018 Jan 16.

15.

How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?

Aubrey BJ, Kelly GL, Janic A, Herold MJ, Strasser A.

Cell Death Differ. 2018 Jan;25(1):104-113. doi: 10.1038/cdd.2017.169. Epub 2017 Nov 17. Review.

16.

DNA-binding of the Tet-transactivator curtails antigen-induced lymphocyte activation in mice.

Ottina E, Peperzak V, Schoeler K, Carrington E, Sgonc R, Pellegrini M, Preston S, Herold MJ, Strasser A, Villunger A.

Nat Commun. 2017 Oct 18;8(1):1028. doi: 10.1038/s41467-017-01022-4.

17.

Coordinated repression of BIM and PUMA by Epstein-Barr virus latent genes maintains the survival of Burkitt lymphoma cells.

Fitzsimmons L, Boyce AJ, Wei W, Chang C, Croom-Carter D, Tierney RJ, Herold MJ, Bell AI, Strasser A, Kelly GL, Rowe M.

Cell Death Differ. 2018 Feb;25(2):241-254. doi: 10.1038/cdd.2017.150. Epub 2017 Sep 29.

18.

The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice.

Brinkmann K, Grabow S, Hyland CD, Teh CE, Alexander WS, Herold MJ, Strasser A.

Cell Death Differ. 2017 Dec;24(12):2032-2043. doi: 10.1038/cdd.2017.125. Epub 2017 Aug 11.

19.

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.

Merino D, Whittle JR, Vaillant F, Serrano A, Gong JN, Giner G, Maragno AL, Chanrion M, Schneider E, Pal B, Li X, Dewson G, Gräsel J, Liu K, Lalaoui N, Segal D, Herold MJ, Huang DCS, Smyth GK, Geneste O, Lessene G, Visvader JE, Lindeman GJ.

Sci Transl Med. 2017 Aug 2;9(401). pii: eaam7049. doi: 10.1126/scitranslmed.aam7049.

PMID:
28768804
20.

An update on using CRISPR/Cas9 in the one-cell stage mouse embryo for generating complex mutant alleles.

Kueh AJ, Pal M, Tai L, Liao Y, Smyth GK, Shi W, Herold MJ.

Cell Death Differ. 2017 Oct;24(10):1821-1822. doi: 10.1038/cdd.2017.122. Epub 2017 Jul 28. No abstract available.

Supplemental Content

Loading ...
Support Center